Physician profile
Mark E Gilder
NPI 1356316525
$7,703.62
in general payments reported to CMS, 2019-2025
30 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,976 · 2020: $243 · 2021: $333 · 2022: $1,318 · 2023: $446 · 2024: $1,789 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190 · Travel and Lodging: $636 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.75 |
| Travel and Lodging | $635.52 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,118.03 | 2019-2025 | |
| Kerecis Limited | $490.43 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Stryker Corporation | $482.81 | 2022 | |
| Medtronic, INC. | $369.06 | 2022-2025 | Eea, Ligasure, Absorbatack |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.63 | 2019-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $161.97 | 2019-2025 | Suflave, Sutab |
| Zyla Life Sciences, INC. | $85.33 | 2019-2020 | |
| Olympus America INC. | $67.50 | 2019-2024 | Olympus, Evis X1 Video System Center |
| Redhill Biopharma INC. | $56.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.01 | 2019-2025 | Entyvio, Eohilia |
| Axonics, INC. | $49.31 | 2023 | Axonics |
| Acera Surgical, INC. | $46.92 | 2025 | Restrata Wound Matrix |
| Mimedx Group, INC. | $46.65 | 2025 | |
| Celgene Corporation | $41.34 | 2022-2023 | Zeposia |
| Acell, INC. | $35.58 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $33.06 | 2023 | New Image, Adapt Ceraring |
| Heron Therapeutics, INC. | $31.93 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $30.52 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $29.18 | 2019-2024 | Rebyota |
| Exact Sciences Corporation | $27.52 | 2024 | Cologuard Collection Kit |
| Kci USA, INC. | $26.44 | 2021 | |
| Merck Sharp & Dohme LLC | $26.29 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $25.31 | 2025 | Myrisk |
| Convatec INC. | $25.11 | 2019 | |
| Thd America, INC. | $19.74 | 2021 | |
| Pfizer INC. | $18.76 | 2025 | |
| Guard Medical INC. | $16.96 | 2023 | Npseal Medium, Npseal Large, Npseal (5) |
| Abbvie INC. | $16.18 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $13.98 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.